APC.V - Advanced Proteome Therapeutics Corporation

TSXV - TSXV Delayed Price. Currency in CAD
0.1450
-0.0050 (-3.33%)
As of 10:59AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1500
Open0.1450
Bid0.1200 x 0
Ask0.1450 x 0
Day's Range0.1450 - 0.1450
52 Week Range0.0800 - 0.9000
Volume500
Avg. Volume13,515
Market Cap3.045M
Beta (3Y Monthly)-0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Does Advanced Proteome Therapeutics Corporation (CVE:APC) Have A High Beta?
    Simply Wall St.2 months ago

    Does Advanced Proteome Therapeutics Corporation (CVE:APC) Have A High Beta?

    Anyone researching Advanced Proteome Therapeutics Corporation (CVE:APC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main...

  • GlobeNewswire7 months ago

    Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma

    Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (APC.V) (0E8.F), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroom toxin amanitin, has led to conjugates that possess high target-specific anti-cancer potency established in several human cancer cell types.

  • We're sorry this is all we were able to find about this topic.